Latest News
-
19th May 2025
ARECOR ESTABLISHES PARTNERSHIP WITH SKYE BIOSCIENCE TO DEVELOP ENHANCED FORMULATION OF OBESITY CANDIDATE NIMACIMAB
-
8th May 2025
ARECOR SELLS RIGHTS TO NON-OGLUO® PRODUCTS
-
26th March 2025
ARECOR ENTERS COLLABORATION WITH MAJOR GLOBAL PHARMACEUTICAL PARTNER
News
-
13/12/2018
Arecor to attend the 37th annual J.P. Morgan healthcare conference
-
29/10/2018
Press Release – Arecor successfully defends a key European patent in opposition proceedings on the subject of mitigation of aggregation of therapeutic proteins during storage
-
15/10/2018
Press release – Arecor joins ELITE Investor Roadshow to China
-
10/09/2018
Press Release – Arecor secures £6m investment for the clinical development of its diabetes speciality pharma portfolio
-
08/08/2018
Press Release – Arecor to give a short course and present at the Bioprocessing Summit, 13th-17th August 2018, Sheraton Boston, Boston, MA, USA
-
02/07/2018
Patent portfolio update – Arecor successfully defends a key European polysaccharide vaccine patent in its opposition proceedings
-
21/06/2018
Press release – Arecor announces Superfast Insulin data presentations at the American Diabetes Association 78th Scientific Sessions
-
19/06/2018
Press release – US$1.3 million grant awarded to Arecor & Manchester Institute of Biotechnology
-
10/05/2018
Arecor to present at the World Congress’ Biologics Formulation and Drug Delivery Technologies Summit 2018 in Boston, MA, USA
-
10/01/2018
Arecor Ltd is pleased to announce the launch of its new website at: www.arecor.com
-
08/01/2018
European patent for Arecor’s proprietary technology enabling highly concentrated biotherapeutics
-
04/01/2018
Arecor and JDRF announce successful pre-clinical development of stable rapid-acting, ultra-concentrated insulin for the significantly enhanced treatment of type 1 diabetes